Drug Profile
AGS 67E
Alternative Names: AGS67ELatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Agensys
- Developer Astellas Pharma
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 Mar 2022 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in Canada (IV, Infusion)
- 28 Mar 2022 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)